Ramantamig clinical trials
Also written JNJ-79635322.
How each study uses ramantamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ramantamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Janssen Research & Development, LLC (7) · University of Heidelberg Medical Center (1)
Often tested with
Tested in the same studies.
Talquetamab (2) · Teclistamab (1) · Dexamethasone (1) · Lenalidomide (1) · Bortezomib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test ramantamig.
- Apr 2027A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisPhase 1 · Janssen Research & Development, LLC
- Jun 2027A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaPhase 2 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses ramantamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleNot yet recruitingPhase 3Janssen Research & Development, LLCNCT07903272Written as Ramantamig
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingPhase 1Janssen Research & Development, LLCNCT05652335Written as JNJ-79635322
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Ramantamig
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07258511Written as JNJ-79635322
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingPhase 2Janssen Research & Development, LLCNCT06500884Written as Ramantamig
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07518186Written as JNJ-79635322
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingPhase 2University of Heidelberg Medical CenterNCT05695508Written as JNJ-79635322
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT07266441Written as JNJ-79635322
Given beside what is tested · 2 — ramantamig is usual care or a partner of the new treatment
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Janssen Research & Development, LLCNCT07589634Written as Ramantamig
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as JNJ-79635322
What changed recently
From the registry's own updates since Oct 17, 2026.
Codes
What other systems call ramantamig · ClinicalTrials.gg INT017156
- UNII (FDA) L97FGF546QRAMANTAMIGOne source FDA
- NCI Thesaurus C216004RamantamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L97FGF546Q | RAMANTAMIG | One source FDA |
| NCI Thesaurus | C216004 | Ramantamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.